Cogent Biosciences Inc

Cogent Therapeutics insider buying fuels confidence in its oncology pipeline—see how CEO moves, reimbursement trends, and AI tech shape biotech’s future.

Fairmount Funds’ March 31 move converts Cogent Biosciences’ preferred stock to 7 M common shares, boosting its stake to ~21% while positioning for upside if clinical milestones hit.

Cogent Biosciences: Fairmount’s 3.5 M-share sale highlights strategic rebalancing, while the firm’s Bezuclastinib pipeline and market‑access plan signal high‑growth biotech potential.